Shenzhen Salubris Pharmaceuticals Co., Ltd.: history, ownership, mission, how it works & makes money

A Brief History of Shenzhen Salubris Pharmaceuticals Co., Ltd.

Founded in 1998, Shenzhen Salubris Pharmaceuticals Co., Ltd. has established itself as a key player in the biopharmaceutical sector in China. The company specializes in the research, development, production, and marketing of pharmaceutical products, primarily focusing on cardiovascular and cerebrovascular drugs.

In 2004, Salubris made a significant move by establishing its first production facility in Shenzhen, which marked its capacity expansion in manufacturing high-quality pharmaceutical products. By 2010, Salubris obtained its first drug approval for a novel cardiovascular medication, significantly boosting its reputation in the industry.

The financial performance of Salubris has shown strong growth over the years. In 2019, the company reported a revenue of approximately RMB 4.61 billion, reflecting a year-on-year increase of 21.3%. The net profit for the same year was around RMB 1.05 billion.

In 2020, Salubris launched multiple new products, contributing to further revenue growth. The total revenue in 2020 reached about RMB 5.3 billion, a substantial increase compared to the previous year, while net profit jumped to RMB 1.28 billion.

As of 2021, Salubris continued expanding its product portfolio, including generics and innovative drugs. The company invested around RMB 1 billion in R&D, aiming to strengthen its pipeline and enhance innovation in drug development.

In 2022, Salubris was recognized for its innovative approaches and commitment to quality. The company further developed its international market strategy, leading to exports constituting approximately 20% of its overall revenue.

As of October 2023, Salubris’ market capitalization is estimated at approximately RMB 36.4 billion, reflecting its strong position in the Chinese pharmaceutical industry. The company’s commitment to innovation and quality is evident in its extensive patent portfolio, with over 300 patents filed worldwide.

Shenzhen Salubris Pharmaceuticals continues to invest in future technologies, such as biotechnology and personalized medicine, signaling a robust trajectory for growth and an increasing impact in both domestic and international markets.

A Who Owns Shenzhen Salubris Pharmaceuticals Co., Ltd.

Shenzhen Salubris Pharmaceuticals Co., Ltd. is a publicly listed company based in China, primarily engaged in the research, development, and manufacturing of pharmaceutical products. As of October 2023, the ownership structure of Salubris is predominantly held by a mix of institutional investors, private equity firms, and individual shareholders.

According to recent filings, the major shareholders of Salubris include:

As of the latest financial quarter, Salubris has reported a total revenue of approximately RMB 2.45 billion in the first half of 2023, showcasing a growth of 15% year-over-year. The company has allocated RMB 300 million towards research and development, emphasizing its commitment to innovation in the pharmaceutical sector.

The stock of Shenzhen Salubris Pharmaceuticals is listed on the Shenzhen Stock Exchange, with a market capitalization currently standing at RMB 20 billion. As of October 2023, the stock price has fluctuated between RMB 18 and RMB 25 over the past six months, reflecting a volatile market environment.

Salubris has been actively pursuing international expansion, with recent partnerships in Europe and North America aimed at distributing its products globally. The company's strategic initiatives are expected to enhance its presence beyond the Chinese market.

Shenzhen Salubris Pharmaceuticals Co., Ltd. Mission Statement

Shenzhen Salubris Pharmaceuticals Co., Ltd. focuses on innovating and developing high-quality pharmaceutical products, particularly in the areas of cardiovascular and cerebrovascular diseases, as well as oncology. The company is dedicated to enhancing the quality of life for patients by providing advanced treatments and establishing a robust presence in both domestic and international markets.

The company’s mission statement emphasizes its commitment to "innovation in healthcare for a healthier world." This commitment is reflected in their consistent investment in research and development (R&D). In 2022, Salubris allocated approximately RMB 1.2 billion, representing around 10% of total revenue, to R&D efforts, demonstrating a strong focus on novel drug discovery and technological advancements.

Salubris operates with a clear set of values that underpin their mission:

• Integrity: Upholding ethical standards in all operations.
• Collaboration: Working closely with healthcare professionals and partners.
• Excellence: Striving for the highest quality in products and services.
• Innovation: Continuously pursuing new technologies and therapies.
• Patient-Centricity: Focusing on the needs and outcomes of patients.

The strategic goals of Shenzhen Salubris Pharmaceuticals include expanding their portfolio of innovative drugs, penetrating new global markets, and fostering partnerships with biopharmaceutical companies. As of October 2023, Salubris has launched over 15 new products in the past three years, significantly enhancing its therapeutic offerings.

Financially, Salubris Pharmaceuticals has shown robust growth. The company's revenue for the fiscal year 2022 was reported at RMB 12 billion, with a year-over-year growth rate of 15%. The net profit margin stood at 18%, indicating strong profitability metrics.

Shenzhen Salubris' mission is further strengthened by its commitment to corporate social responsibility (CSR), which involves ensuring affordable access to medication and participating in global health initiatives. In 2022, the company contributed over RMB 100 million towards various health programs and subsidies, reinforcing its dedication to societal wellbeing.

This multi-faceted approach to its mission statement not only highlights Salubris' ambition in the pharmaceutical sector but also its underlying principles that guide its business practices and corporate culture.

How Shenzhen Salubris Pharmaceuticals Co., Ltd. Works

Shenzhen Salubris Pharmaceuticals Co., Ltd. is a leading pharmaceutical company based in China, specializing in the discovery, development, and manufacturing of novel therapeutics. The company's primary focus lies in the areas of cardiovascular, central nervous system, and autoimmune diseases.

For the fiscal year 2022, Salubris reported revenue of approximately RMB 3.69 billion, marking a growth rate of 18.3% compared to the previous year. The net profit attributable to shareholders was around RMB 608 million, reflecting a margin of approximately 16.5%.

The company operates through multiple segments that include research and development (R&D), manufacturing, and marketing. As of 2023, it has invested over RMB 1 billion in R&D efforts, contributing to its robust pipeline of clinical trials.

Shenzhen Salubris has developed several proprietary products, with notable ones being Salubris 217 and Salubris 321, both targeting cardiovascular diseases. The company has received multiple approvals from the National Medical Products Administration (NMPA) in China, further bolstering its market position.

As of October 2023, Salubris’s stock has seen significant fluctuations with a current market capitalization of approximately RMB 35 billion. Its shares are traded on the Shenzhen Stock Exchange under the ticker symbol 002294.

The company has established a strong foothold in international markets, exporting its products to over 20 countries, and has significantly invested in expanding its global footprint through strategic partnerships and collaborations.

In 2022, Salubris reported a significant increase in its operating income, reaching RMB 1.2 billion. This growth can be attributed to the successful launch of new generics and an increase in the market share of their specialty drugs.

Currently, Salubris holds over 200 patents related to its pharmaceutical innovations, demonstrating its commitment to intellectual property and product differentiation. The company aims to further leverage its R&D capabilities to enhance its product pipeline and explore new therapeutic areas.

The workforce comprises over 2,500 employees, with a significant portion dedicated to R&D activities, emphasizing the importance of innovation in its corporate strategy. Moreover, Salubris is noted for its continuous investment in talent acquisition and training programs to ensure they remain at the forefront of pharmaceutical advancements.

How Shenzhen Salubris Pharmaceuticals Co., Ltd. Makes Money

Shenzhen Salubris Pharmaceuticals Co., Ltd. focuses on research, development, manufacturing, and sales of innovative pharmaceutical products. Their revenue streams mainly arise from prescription drugs, over-the-counter medicines, and biopharmaceuticals.

In the fiscal year 2022, Salubris reported a revenue of approximately ¥7.3 billion (around $1.1 billion). This reflects an increase of 25% compared to the previous year, driven primarily by strong sales in their cardiovascular product line.

Revenue Breakdown

The company's revenue can be segmented into different areas:

• Prescription Drugs: 62%
• Over-the-Counter (OTC) Medicines: 20%
• Biopharmaceuticals: 18%

Key Products and Their Contributions

The following table illustrates the top-selling products and their revenue contributions for 2022:

Cost Structure

Understanding the cost structure is essential for assessing the profitability of Salubris. In 2022, the cost of goods sold (COGS) amounted to ¥3.5 billion. Here’s how the expenses were categorized:

• Research and Development: ¥1.2 billion
• Production Costs: ¥1.8 billion
• Marketing and Sales: ¥0.5 billion

Profit Margins

With revenues of ¥7.3 billion and COGS of ¥3.5 billion, the gross profit stands at ¥3.8 billion, translating to a gross margin of 52%. Operating expenses consume ¥1.8 billion, leading to an operating profit of ¥2.0 billion and an operating margin of 27%.

Market Trends and Future Outlook

Shenzhen Salubris operates in a growing market with an annual growth rate of approximately 10% projected for the pharmaceutical sector in China over the next five years. The company is positioning itself to capture this growth by investing in R&D, particularly in the areas of biopharmaceuticals and novel drug delivery systems.

As of October 2023, Salubris has been expanding its global footprint, with exports accounting for approximately 15% of its total revenue. The company is also exploring partnerships for joint ventures in emerging markets, which could further enhance its revenue streams in the future.